RayzeBio, Inc.
RYZBDelisted Feb 26, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001825367
RayzeBio, Inc. was delisted on Feb 26, 2024; its insiders filed their last Form 4 on Feb 28, 2024; 107 institutions reported holding it in 13F filings for Q4 2023, worth $3.40B in total; superinvestors Viking Global Investors and HHLR Advisors (Hillhouse) held it.
Q1 2024 vs. Q4 2023
How the institutions holding RayzeBio, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Of which not filed for Q1 2024 | Q1 2024 | Change |
|---|---|---|---|---|
| Holders | 107 | 1 | 0 | −106 |
| Shares | 54.8M | 12.2K | 0 | −54.7M (−100.0%) |
| Value | $3.40B | $758.0K | $0 | −$3.40B (−100.0%) |
1 institution that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (0)
Institutions that held RayzeBio, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
None.
Sold out (106)
Institutions that held RayzeBio, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
Showing the largest 100 of 106 by value.
Not filed for Q1 2024 yet (1)
Institutions that held RayzeBio, Inc. at the end of Q4 2023 and haven't filed a 13F for Q1 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Kellner Capital, LLC | 12,200 | $758.0K |